Results 81 to 90 of about 386,039 (382)

Role for non-proteolytic control of M-phase-promoting factor activity at M-phase exit.

PLoS ONE, 2007
M-phase Promoting Factor (MPF; the cyclin B-cdk 1 complex) is activated at M-phase onset by removal of inhibitory phosphorylation of cdk1 at thr-14 and tyr-15. At M-phase exit, MPF is destroyed by ubiquitin-dependent cyclin proteolysis.
Vincenzo D'Angiolella, Luca Palazzo, Concetta Santarpia, Vincenzo Costanzo, Domenico Grieco   +4 more
doaj   +1 more source

Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1.

Journal of Clinical Investigation, 2012
Altered lipid metabolism underlies several major human diseases, including obesity and type 2 diabetes. However, lipid metabolism pathophysiology remains poorly understood at the molecular level.
Xiaoping Zhao, Daorong Feng, Qun Wang, A. Abdulla, Xiao-Jun Xie, Jie Zhou, Y. Sun, Ellen S. T. Yang, Lu-ping Liu, B. Vaitheesvaran, Lauren Bridges, I. Kurland, R. Strich, Jianquan Ni, Chenguang Wang, J. Ericsson, J. Pessin, J. Ji, Fajun Yang   +18 more
semanticscholar   +1 more source

Determination of ADP/ATP translocase isoform ratios in malignancy and cellular senescence

Molecular Oncology, EarlyView.
The individual functions of three isoforms exchanging ADP and ATP (ADP/ATP translocases; ANTs) on the mitochondrial membrane remain unclear. We developed a method for quantitatively differentiating highly similar human ANT1, ANT2, and ANT3 using parallel reaction monitoring. This method allowed us to assess changes in translocase levels during cellular
Zuzana Liblova, Dominika Maurencova, Barbora Salovska, Marek Kratky, Tomas Mracek, Zuzana Korandova, Alena Pecinova, Pavla Vasicova, David Rysanek, Ladislav Andera, Ivo Fabrik, Rudolf Kupcik, Pavel Kashmel, Pinky Sultana, Vojtech Tambor, Jiri Bartek, Josef Novak, Marie Vajrychova, Zdenek Hodny   +18 more
wiley   +1 more source

An RB insensitive to CDK regulation

Molecular & Cellular Oncology, 2017
The N-term phosphorylation of Retinoblastoma (RB) by the p38 stress-activated protein kinase (SAPK) makes RB insensitive to cyclin-dependent kinase (CDK)-Cyclin inhibition, which enhances the transcriptional repression of E2F-driven promoters and delays ...
Manel Joaquin, Eulàlia de Nadal, Francesc Posas   +2 more
doaj   +1 more source

Overview of Current Type I/II Kinase Inhibitors [PDF]

arXiv, 2018
Research on kinase-targeting drugs has made great strides over the last 30 years and is attracting greater attention for the treatment of yet more kinase-related diseases. Currently, 42 kinase drugs have been approved by the FDA, most of which (39) are Type I/II inhibitors.
arxiv  

Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II

Nature Structural &Molecular Biology, 2012
Promoter-proximal pausing by RNA polymerase II (Pol II) ensures gene-specific regulation and RNA quality control. Structural considerations suggested a requirement for initiation-factor eviction in elongation-factor engagement and pausing of ...
S. Larochelle, Ramon Amat, Kira M. Glover-Cutter, M. Sansó, Chao Zhang, J. Allen, K. Shokat, D. Bentley, R. Fisher   +8 more
semanticscholar   +1 more source

Strategies to reduce the cancer burden and improve access to effective and affordable cancer interventions in Europe

Molecular Oncology, EarlyView.
Comprehensive cancer centre (CCCs) and CCCs of Excellence (CCCoE) integration in healthcare. Through outreach to surrounding community hospitals, CCCs enable wider access to top‐clinical cancer treatments and care, thereby facilitating the swift enrolment of patients into data‐rich clinical trials (PI‐initiated trials testing new concepts, drug ...
Anton Berns, Ulrik Ringborg, Julio Celis, Bengt Jönsson, Michael Baumann   +4 more
wiley   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

CDK12/CDK13: New Hope for Targeted Therapy of Human Malignant Tumors

Zhongliu Fangzhi Yanjiu
Cell cycle turnover depends on cyclin-dependent kinase (CDKs). CDK is the protein kinase family that plays the key role in regulating cell cycle and gene transcription.
CHEN Kaixing, WU Zhouying, YU Lan
doaj   +1 more source

A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia

Brazilian Journal of Medical and Biological Research, 2014
p15INK4B, a cyclin-dependent kinase inhibitor, has been recognized as a tumor suppressor. Loss of or methylation of the p15INK4B gene in chronic myeloid leukemia (CML) cells enhances myeloid progenitor formation from common myeloid progenitors. Therefore,
D.Y. Xia, L. Liu, M.W. Hao, Q. Liu, R.A. Chen, Y.M. Liang   +5 more
doaj   +1 more source